North America Intravenous Ibuprofen Market

North America Intravenous Ibuprofen Market Size & Growth (2023 to 2028):

As per the research report, the size of the North America Intravenous Ibuprofen Market is valued at USD 3.44 billion in 2023 and estimated to be growing at a CAGR of 19.62%, reaching USD 8.29 billion by 2028 during the forecast period 2023 to 2028.

Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory medicine (NSAID) used to relieve or treat pain, fever, and inflammation caused by a disease, operational procedures or injuries, or acute illness.

One of the most important features is that intravenous (IV) ibuprofen administration has a faster beginning of action than the other routes. Therefore, IV ibuprofen is preferable for treating post-operative and acute pain. In addition, the side effects of opioid analgesics, such as respiratory depression, allergic responses, drowsiness, and gastrointestinal problems, have raised the demand for ibuprofen.

The increased popularity of an intravenous method of drug delivery for acute pain management due to faster onset of action compared to other routes, oral and transdermal mode of administration, and targeted drug delivery property are among the primary factors driving market expansion.

The increased popularity of an intravenous method of drug delivery for acute pain management due to faster onset of action than other administration routes such as oral and transdermal modes of administration and targeted drug delivery properties are among the primary factors driving market expansion.

Another key aspect is that IV ibuprofen helps pain management while reducing reliance on opioid analgesic medications, which can cause drowsiness, disorientation, and other side effects. The sole injectable ibuprofen medication on the market is Cal dolor Cumberland Pharmaceuticals.

There's a lot of demand, but there's not a lot of competition. However, several constraints, such as the lengthy clearance procedure and the restricted geographic coverage of North America, are expected to hinder market expansion.

The side effects of opioid analgesics, such as respiratory depression, allergic responses, drowsiness, and gastrointestinal problems, have raised the demand for ibuprofen.

This research report on the North America Intravenous Ibuprofen Market has been segmented and sub-segmented into the following categories:

By Age Group:

• Adults
• Pediatrics

By Indication:

• Fever
• Pain/inflammatory

By Country:

• U.S
• Canada
• Rest of North America

Geographically, the North America has the largest market share in the world. In addition, due to the widespread use of IV Ibuprofen for pain and fever treatment, the United States is expected to be the top revenue-generating region during the projected period.

The U.S Intravenous Ibuprofen Market increases knowledge of non-steroidal anti-inflammatory medicines and a trend in drug delivery toward intravenous. The need for intravenous ibuprofen for pain management is still in its infancy. However, the benefits of IV ibuprofen, such as speedy results and tailored medication distribution, have contributed to the market's rise.

The Canada Intravenous Ibuprofen Market has resulted in the market's growth with a decent CAGR during the period. The FDA approved IV ibuprofen for pediatric use in 2015, and the market is likely to rise significantly throughout the projection period. Other key factors influencing the market growth include growing cancer, cardiovascular disease, pain, headache, toothache, back pain, arthritis, trauma, and a shift in non-opioids medications.

KEY MARKET PLAYERS

Prominent companies playing a dominant role in the North America Intravenous Ibuprofen Market profiled in this report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc., CSL Limited, Sandor Medicaids Pvt Ltd., Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., PT. Soho Industri Pharmasi, and Laboratorios Valmorca, C.A.,